CNF 2017 Annual Educational Initiative: SUDEP

Posted on:

Each year, CNF selects a topic to be the focus of its child neurology community educational initiative. For 2017, CNF selected Sudden Unexplained Death in Epilepsy (SUDEP) in children. SUDEP is when a seemingly healthy person with epilepsy dies unexpectedly and no clear reason for the death can be determined. The risk…  Read More

Cerebral Palsy is a Diagnosis, Not a Destiny: NEW OFFERINGS

Posted on:

CCPM is on the Move Children’s Cerebral Palsy Movement (CCPM) executed a successful multi-institutional, multi-disciplinary scientific pilot study, involving boys & girls with CP that demonstrated improvements in both cognitive and physical function. As CCPM has gotten to meet and know more families impacted by CP, they have come to…  Read More

NEW INTERACTIVE GRAPHIC: Tools for Transitioning Young Adults with Neurologic Conditions

Posted on:

Led by CNF, the consensus statement, The Neurologist’s Role in Supporting Transition to Adult Health Care* was published in July 2016. The statement identifies 8 Common Principles for the neurology team to adapt and employ-supporting the medical transition of your with neurologic conditions. To move policy into practice-ideally resulting in successful transitions-the CNF…  Read More

Midazolam Nasal Spray (USL261) Phase 3 Trial Meets Primary Efficacy Endpoint In Patients With Seizure Clusters

Posted on:

CAMBRIDGE, England, April 26, 2017 /PRNewswire/ — Proximagen Limited (Proximagen) today announced that its pivotal Phase 3 trial of intranasal midazolam (USL261) for the rescue treatment of seizure clusters, met its primary efficacy endpoint in a top-level analysis of the data. Based on these findings, Proximagen will approach the U.S. Food…  Read More

Exciting advancement for adolescents living with migraines!

Posted on:

FDA Approves Expanded Indication for Qudexy® XR (topiramate) Extended-Release Capsules to Include Prophylaxis of Migraine Headache in Adults and Adolescents Molecule Most Prescribed by Neurologists for Migraine Prophylaxis Now Available in a Unique 24-hour Formulation MAPLE GROVE, Minn., March 30, 2017 /PRNewswire/ — Upsher-Smith Laboratories, Inc. (Upsher-Smith) today announced that…  Read More

Rare Neurological Disease Special Report

Posted on:

Neurology Reviews presents its third annual Rare Neurological Disease Special Report, a compendium of articles and information covering a wide range of rare neurologic diseases. CNF is committed to the awareness and education of these rare conditions as evidenced by its newly-convened RARE Child Neurology Workgroup – a collaborative workgroup with…  Read More

Novartis drug Votubia® receives EU approval to treat refractory partial-onset seizures in patients with TSC

Posted on:

MEDIA RELEASE • COMMUNIQUE AUX MEDIAS Novartis International AG Novartis Global Communications CH-4002 Basel Switzerland http://www.novartis.com • MEDIENMITTEILUNG Novartis drug Votubia® receives EU approval to treat refractory partial-onset seizures in patients with TSC   Votubia is the first adjunctive treatment approved in the EU specifically for partial- onset seizures in…  Read More

Posted on:

Creatine helps supply energy to all cells in the body. It helps increase adenosine triphosphate (ATP). Creatine is produced in the liver, which makes it out of three amino acids: arginine, glycine and methionine. Most of our body’s creatine (approximately 95%) is stored in the muscles that support the skeleton….  Read More

Novartis drug Votubia® receives EU approval to treat refractory partial-onset seizures in patients with TSC

Posted on:

Basel, January 31, 2017 – Novartis today announced that the European Commission has approved Votubia® (everolimus) dispersible tablets* as an adjunctive treatment for patients aged two years and older whose refractory partial-onset seizures, with or without secondary generalization, are associated with tuberous sclerosis complex (TSC). Votubia is now the first…  Read More